Granted Patent
B2
US 12,364,716 · App. 18/379,955 · Granted Jul 22, 2025
Compositions and methods for treating and preventing tissue injury and disease
Inventors:
Dale R. Peterson (Carlsbad, CA); Ralph-Heiko Mattern (Ramona, CA); Kevin L. Ohashi (Jamaica Plain, MA); Lael J. Pickett (White Bear Lake, MN); Glen Gong (San Carlos, CA); Mohammad A. El-Kalay (Carlsbad, CA)
Assignee:
MicroVascular Tissues, Inc.
A61K35/44A61K35/12A61K35/545A61L27/3625A61L27/3687A61L27/3691A61L27/3834A61L27/3878A61L27/54C12N5/0653A61L2300/41A61L2300/412A61L2400/06A61L2430/02A61L2430/06A61L2430/10A61L2430/32A61L2430/34A61L2430/38
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.
Claims (18)
1. A composition comprising enriched or isolated multipotent cells from dissociated mammalian tissue, wherein the composition is sterilized by irradiation, and wherein the composition has angiogenic or anti-inflammatory activity.
2. The composition of claim 1 , wherein the cells or tissue are not cultured.
3. The composition of claim 1 , wherein the composition comprises ten or more components of multipotent cells.
4. The composition of claim 1 , wherein at least 50% of the multipotent cells present in the composition will not proliferate.
5. The composition of claim 1 , wherein the composition comprises one or more vessel wall extracellular matrix components.
6. The composition of claim 1 , wherein the composition comprises one or more growth factors.
7. The composition of claim 1 , wherein the composition comprises one or more angiogenic agents.
8. The composition of claim 1 , wherein the dissociated mammalian tissue is a non-embryonic tissue.
9. The composition of claim 8 , wherein the non-embryonic tissue is adipose tissue, skin, bone, tendon tissue, post-partum tissue, umbilical cord tissue, placental tissue, bone marrow or muscle tissue.
10. A composition comprising dissociated mammalian tissue, wherein the composition comprises multipotent cells rendered nonviable, and wherein the composition has angiogenic or anti-inflammatory activity.
11. The composition of claim 10 , wherein the composition is sterilized by irradiation.
12. The composition of claim 10 , wherein viruses within the composition are inactivated.
13. The composition of claim 10 , wherein the cells or tissue are not cultured.
14. The composition of claim 10 , wherein the composition comprises one or more vessel wall extracellular matrix components.
15. The composition of claim 10 , wherein the composition comprises one or more growth factors.
16. The composition of claim 10 , wherein the composition comprises one or more angiogenic agents.
17. The composition of claim 10 , wherein the dissociated mammalian tissue is a non-embryonic tissue.
18. The composition of claim 17 , wherein the non-embryonic tissue is adipose tissue, skin, bone, tendon tissue, post-partum tissue, umbilical cord tissue, placental tissue, bone marrow or muscle tissue.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 14, 2024
From: PETERSON, DALE R.; MATTERN, RALPH-HEIKO; OHASHI, KEVIN L.; PICKETT, LAEL J.; GONG, GLEN; EL-KALAY, MOHAMMAD A.
To: MICROVASCULAR TISSUES, INC.
Reel/Frame 069261/0469 →
Continuity (7)
References Cited (120)
US 5358931A
· Rubinsky et al.
· 1994
[cited by applicant]
US 5656498A
· Iijima et al.
· 1997
[cited by applicant]
US 5730933A
· Peterson
· 1998
[cited by applicant]
US 5786207A
· Katz et al.
· 1998
[cited by applicant]
US 6200606B1
· Peterson et al.
· 2001
[cited by applicant]
US 7125856B1
· Isner
· 2006
[cited by applicant]
US 7270946B2
· Brockbank et al.
· 2007
[cited by applicant]
US 7344716B2
· DiMauro et al.
· 2008
[cited by applicant]
US 7560276B2
· Harmon et al.
· 2009
[cited by applicant]
US 7659111B2
· Meir et al.
· 2010
[cited by applicant]
US 8048671B2
· Hendriks et al.
· 2011
[cited by applicant]
US 8119398B2
· Sayre et al.
· 2012
[cited by applicant]
US 9044430B2
· Peterson et al.
· 2015
[cited by applicant]
US 9713629B2
· Peterson et al.
· 2017
[cited by applicant]
US 9872937B2
· Peterson et al.
· 2018
[cited by applicant]
US 20020091444A1
· Yang
· 2002
[cited by applicant]
US 20070292401A1
· Harmon et al.
· 2007
[cited by applicant]
US 20080033572A1
· D'Antonio et al.
· 2008
[cited by applicant]
US 20080286323A1
· Tornoe et al.
· 2008
[cited by applicant]
US 20100068245A1
· Manders
· 2010
[cited by applicant]
US 20100256692A1
· Kang et al.
· 2010
[cited by applicant]
US 20110189140A1
· Christman et al.
· 2011
[cited by applicant]
US 20120301507A1
· Zheng
· 2012
[cited by applicant]
US 20140017787A1
· Betancourt
· 2014
[cited by applicant]
US 20190091261A1
· Peterson et al.
· 2019
[cited by applicant]
US 20200353008A1
· Peterson et al.
· 2020
[cited by applicant]
CN 1822824A
· 2006
[cited by applicant]
CN 101505796A
· 2009
[cited by applicant]
CN 101757691A
· 2010
[cited by applicant]
CN 102227225A
· 2011
[cited by applicant]
CN 102481318A
· 2012
[cited by applicant]
CN 104955464A
· 2015
[cited by applicant]
EP 0668013A2
· 1995
[cited by applicant]
EP 1576957A1
· 2005
[cited by applicant]
JP 2010240379A
· 2010
[cited by applicant]
JP 2015529687A
· 2015
[cited by applicant]
WO WO9726326A1
· 1997
[cited by applicant]
WO WO2004006961A1
· 2004
[cited by applicant]
WO WO2004022078A1
· 2004
[cited by applicant]
WO WO2005035742A2
· 2005
[cited by applicant]
WO WO2006006337A1
· 2006
[cited by applicant]
WO WO2007015252A2
· 2007
[cited by applicant]
WO WO2007142651A1
· 2007
[cited by applicant]
WO WO2007149861A2
· 2007
[cited by applicant]
WO WO2008013863A2
· 2008
[cited by applicant]
WO WO2009115581A2
· 2009
[cited by applicant]
WO WO2009134532A2
· 2009
[cited by applicant]
WO WO2010016942A1
· 2010
[cited by applicant]
WO WO2012024573A2
· 2012
[cited by applicant]
WO WO2012031162A1
· 2012
[cited by applicant]
WO WO2012154301A1
· 2012
[cited by applicant]
WO WO2012170905A1
· 2012
[cited by applicant]
WO WO2014047067A1
· 2014
[cited by applicant]
WO WO2017151950A1
· 2017
[cited by applicant]
WO WO2019136455A1
· 2019
[cited by applicant]
Apfel, S. C., “Neurotrophic factors in peripheral neuropathies: therapeutic implications,” Brain Pathol., Apr. 1999, pp. 393-413.
[cited by applicant]
Aslan, H. et al., Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells, 24(7):1728-1737. (2006).
[cited by applicant]
Baer, P. C. et al., Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells International, Article ID 812693, 11 pages. Epub Apr. 12, 2012. (2012).
[cited by applicant]
Bushkalova et al., Polyelectrolyte scaffolds for cardiac mesenchymal stem cell therapy. Wound Repair and Regeneration, 21(6): 1 page A59 (Nov.-Dec. 2013).
[cited by applicant]
Chen, C., et al. Human Blood-Vessel-Derived Stem Cells for Tissue Repair and Regeneration. J Biomed Biotechnol.; 2012: 597439, 10 pages. (2012) Published online Feb. 2, 2012.
[cited by applicant]
Dulmovits, B. M., et al. Microvascular Remodeling and Wound Healing: A Role for Pericytes. Int J Biochem Cell Biol.; 44(11):1800-12. (Nov. 2012) Epub Jun. 28, 2012.
[cited by applicant]
Fortino, V. R. et al., Concise Review: Stem Cell Therapies for Neuropathic Pain. Stem Cells Transl Med. 2(5): 394-399. (May 2013). Published online Apr. 9, 2013.
[cited by applicant]
Han, J. W. et al., Cell Therapy for Diabetic Neuropathy Using Adult Stem or Progenitor Cells. Diabetes Metab J. 37(2): 91-105. (Apr. 2013). Published online Apr. 16, 2013.
[cited by applicant]
Hanson, S. E. et al., Clinical Applications of Mesenchymal Stem Cells in Soft Tissue Augmentation, Aesthet Surg J., 30(6):838-842. (2010).
[cited by applicant]
Hanson, S. E. et al., Mesenchymal Stem Cell Therapy for Nonhealing Cutaneous Wounds. Plastic Reconstr. Surg., 125(2):510-516. (2010).
[cited by applicant]
Harris, P.F., “The Correlation between bone marrow activity and blood neutrophil levels from quantitative studies in irradiated guinea-pigs”, Department of Anatomy, The University, Bristol, May 19, 1959, 13 pages.
[cited by applicant]
Iaea, Radiation sterilization of tissue allografts: Requirements for Validation and routine control—A code of practice, IAEA, Vienna. (2007). 65 total pages.
[cited by applicant]
Iyer, S. S. et al., Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies, Expert Opin. Biol. Ther., 8(5):569-581.(2008).
[cited by applicant]
Janicki, P. et al., “Prediction of in vivo bone forming potency of bone marrow-derived human mesenchymal stem cells”, European Cells and Materials, 2011, vol. 21, pp. 488-507, 20 pages.
[cited by applicant]
Lim, J. S. et al., Effects of Adipose-derived Stromal Cells and of their Extract on Wound Healing in a Mouse Model, J Korean Med Sci, 25(5):746-751. (2010).
[cited by applicant]
Liu, G., et al. Transplantation of adipose-derived stem cells for peripheral nerve repair. Int J Mol Med.; 28(4):565-72. (Oct. 2011) Epub Jun. 17, 2011.
[cited by applicant]
Park et al., “Analysis of Irradiation on the Clinical Effectiveness of Allogenic Tissue When Used for Primary Anterior Cruciate Ligament Reconstruction”, The American Journal of Sports and Medicine, vol. 43, No. 1, 2015…
[cited by applicant]
Rainey, F. A., et al. Extensive diversity of ionizing-radiation-resistant bacteria recovered from Sonoran Desert soil and description of nine new species of the genus
[cited by applicant]
Rayner, et al., Engineered Microvessels for the Study of Human Disease, Journal of biomechanical engineering, Nov. 2016, 11 pages.
[cited by applicant]
Ronaghi, M. et al. “Challenges of stem cell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells?”, Stem Cells. 28(1):93-9. (Jan. 2010).
[cited by applicant]
Rosova, I. et al., Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells, Stem Cells, 26: 2173-2182 (2008).
[cited by applicant]
Samsell, B. J., et al. Use of controlled low dose gamma irradiation to sterilize allograft tendons for ACL reconstruction: biomechanical and clinical perspective. Cell Tissue Bank.; 13(2):217-23. (Jun. 2012) Epub Mar. 2…
[cited by applicant]
Shao et al., “Hematopoetic Stem Cell Injury Induced by Ionizing Radiation”, Antioxidants & Redox Signaling, vol. 20, No. 9, 2014, 16 pages.
[cited by applicant]
Smith, C. W. (1996). Mechanical Properties of Tendons: Changes With Sterilization and Preservation. Journal of Biomechanical Engineering, 118(1), 56-61 doi:10.1115/1.2795946.
[cited by applicant]
Volarevic, V. et al. “Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus”, Stem Cells. 29(1):5-10. (Jan. 2011).
[cited by applicant]
Wang, E-T et al., Regulation of tissue repair and regeneration by electric fields. Chinese Journal of Traumatology. 13(1):55-61 (2010).
[cited by applicant]
Whang, P.G. et al., Bone graft substitutes for spinal fusion. Spine J. 3:155-165. (2003).
[cited by applicant]
Wierenga et al., Protection against radiation-induced damage to salivary glands by stem cell transplantation. Blood, 100(11) Abstract No. 4121, Nov. 16, 2002, pp. 158B-159B.
[cited by applicant]
World Health Organization, “Aide-Memoire on Key Safety Requirements for Essential Minimally Processed Human Cells and Tissues for Transplantation”; WHO; 2006; 21 pages.
[cited by applicant]
World Health Organization, “Second Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation: Towards Global Harmonization through Graduated Standards”; WHO Geneva, Jun. 7-9, 2006; 4…
[cited by applicant]
Wu, Q. et al., Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot. Stem Cells Int. 2016: 4612167. (2016). Published online Oct. 27, 2016.
[cited by applicant]
Yagihashi, S., et al. Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Investig.; 2(1): 18-32. (Feb. 1, 2011) Published online Oct. 6, 2010.
[cited by applicant]
Yew, T-L et al., Enhancement of wound healing by human multipotent stromal cell conditioned medium: the paracrine factors and p38 MAPK activation. Cell Transplantation, 20: 693-706 (2011). Epub Dec. 2010.
[cited by applicant]
Yoshimura, K. et al., Adipose-derived stem/progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. Regenerative Medicine, 4(2):265-273 (2009).
[cited by applicant]
Zarandi, P. et al., Ps-43: Serum-free isolation of adipose tissue derived multipotent mesenchymal stromal cells. (Abstract), Abstracts of the 6th Royan International Congress on Stem Stell Biology & Technology, Yakhteh …
[cited by applicant]
Zhou, J. Y., et al., “Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic,” Cell death discovery, Jul. 11, 2016, vol. 2:16055, pp. 1-7.
[cited by applicant]